Beyond diagnostics, artificial intelligence is extending into therapeutics, emergency care, and surgery, and the AI in neurology market is expanding accordingly. Valued at USD 759.2 million in 2025, the market is projected to reach USD 945.6 million in 2026 and USD 5,619.9 million by 2034, growing at a CAGR of 25.0% during the forecast period 2026–2034. Key players include Activ Surgical, Airamed GmbH, Brainomix Limited, BrainQ Technologies Ltd., Canon Inc., GE Healthcare, Koninklijke Philips N.V., Medtronic Plc, Neosoma Inc., Neuralink Corporation, Neurox, NVIDIA Corporation, Qure.AI, Siemens Healthineers AG, and Viz.ai Inc. This article examines the applications and regional dynamics driving the next growth phase.

AI Drug Discovery Opens a High-Growth Application Area

The drug discovery application is projected to grow at a CAGR of 25.4% during the forecast period, driven by rising use of AI drug discovery platforms to identify novel central nervous system therapies. AI models accelerate target identification, biomarker discovery, and clinical trial optimization. Pharma companies are projected to be the fastest-growing end-user group as they invest in AI for drug development and clinical research. In April 2026, Brenig Therapeutics introduced a drug discovery approach combining physics-based structural biology with AI modeling. Polaris notes that pharmaceutical organizations are partnering with AI businesses to expedite discovery and testing of new drugs, while mergers and acquisitions are becoming more common as large healthcare technology firms acquire AI capabilities through niche deals. Investment trends also favor the segment, as neurology-focused AI companies are receiving substantial funding because of the need for innovative diagnostic tools.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/ai-in-neurology-market

Stroke Detection Demonstrates Measurable Clinical Value

Stroke detection is among the most visible real-world uses of the technology. AI analyzes CT and MRI scans in real time to identify stroke patterns and support faster treatment decisions. In October 2024, Viz.ai published findings showing that its AI-enabled stroke care coordination platform reduced interfacility stroke transfer times by 44%. In February 2024, UC Davis Health implemented Viz.ai's AI-driven technology to accelerate identification of suspected stroke patients through automated CT scan analysis, and in February 2025 Viz.ai announced study results showing improved treatment timelines, care coordination efficiency, and financial outcomes for neurovascular patients. These results reinforce the return-on-investment case for hospitals: shorter diagnostic periods, higher imaging precision, and streamlined workflows through stroke detection tools.

Early Disease Detection and AI Neurosurgery

An aging population is accelerating the need for early disease detection and continuous monitoring. According to the United Nations, the global population aged above 65 is projected to outgrow the population aged below 18 in the 2070s. Diagnostics held a 40.5% share in 2025 on the adoption of tools for early detection and accurate assessment of neurological disorders. AI neurosurgery represents a further growth pathway; the report segments neurosurgery as a distinct application alongside diagnostics and drug discovery, and notes that algorithms are increasingly used in AI neurosurgery for risk assessment, surgical planning, and outcome prediction. Alzheimer's Disease International estimates that dementia cases will reach 78 million by 2030 and 139 million by 2050, underscoring the long-term need. Medtronic Plc and Activ Surgical are among the participants profiled in the report. Early disease detection remains the clinical objective linking these applications.

AI in Neurology Market: Regional Dynamics and Competitive Landscape

North America dominated with a 40.63% revenue share, as the US leads with advanced clinical infrastructure and high integration of AI in Neurology. Europe is shaped by strict regulatory compliance and a strong focus on AI ethics, with patient data privacy and transparency prioritized. Asia Pacific is witnessing rapid growth at a 25.6% CAGR, while the Middle East is moving toward smarter hospitals and Latin America remains at an early adoption stage. The industry is moderately concentrated, and investment is flowing to neurology-focused AI companies developing innovative diagnostic tools. As AI drug discovery, stroke detection, biomarker discovery, early disease detection, and AI neurosurgery gain clinical validation, the market is projected to grow from USD 945.6 million in 2026 to USD 5,619.9 million by 2034.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market